<!-- Main Content Component for Closer Look at Leiomyosarcoma Page -->
<div class="main-content">
    <!-- WebMD Reference Section -->
    <div id="webmd-resource" class="content-section reference-section">
        <div class="reference-card">
            <div class="reference-header">
                <i class="fas fa-external-link-alt"></i>
                <h2>WebMD Resource</h2>
            </div>
            <p class="reference-description">Exploring Imaging Tests, Biopsies, Treatment Options, and Ongoing Care</p>
            <a href="https://www.webmd.com/cancer/leiomyosarcoma-diagnosis" target="_blank" rel="noopener noreferrer" class="reference-link">
                <i class="fas fa-link"></i>
                View WebMD Leiomyosarcoma Diagnosis Guide
            </a>
        </div>
    </div>

    <!-- Diagnostic Tests Section -->
    <div id="diagnostic-approaches" class="content-section diagnostic-section">
        <h2 class="section-title">
            <i class="fas fa-stethoscope"></i>
            Comprehensive Insights into Diagnostic Approaches
        </h2>
        <p class="section-intro">The following tests and procedures may be used to detect and diagnose soft tissue cancer:</p>

        <!-- Medical History -->
        <div class="test-category">
            <h3 class="category-title">
                <i class="fas fa-clipboard-list"></i>
                Medical History and Physical Exam
            </h3>
            <p>By now you will have had discussions with your oncologist about your medical history, any recent illnesses, injuries, new symptoms of note, medications you are taking, and family history information.</p>
        </div>

        <!-- Blood Tests -->
        <div class="test-category">
            <h3 class="category-title">
                <i class="fas fa-vial"></i>
                Blood Tests
            </h3>
            <p>Tests are not used to diagnose soft tissue sarcoma, but rather for signs of disease and assessment of your general health. Blood tests may be used to assess the response to drug treatment. Abnormal levels of certain chemicals in the blood can also be an assessment of the cancer having spread elsewhere in the body.</p>
            
            <div class="sub-category">
                <h4>Comprehensive Metabolic Panel</h4>
                <p>A comprehensive metabolic panel may involve testing up to 14 different chemicals in your blood. Deviations from normal levels can be indicative of cancer or other health concerns. This panel assesses chemicals originating from various organs, including the liver and bones.</p>
            </div>

            <div class="sub-category">
                <h4>Complete Blood Count and Differential (CBC)</h4>
                <p>CBC measures the quantity of different blood cells present in a blood sample, including white blood cells.</p>
            </div>
        </div>

        <!-- Physical Examination -->
        <div class="test-category">
            <h3 class="category-title">
                <i class="fas fa-user-md"></i>
                Physical Examination
            </h3>
            <p>A comprehensive physical examination will be conducted to detect any signs of disease, such as lumps or other abnormal findings. A lump or bump should not be dismissed but rather evaluated to rule out the possibility of it being a form of sarcoma.</p>
            
            <div class="video-resources">
                <h4>Educational Videos:</h4>
                <div class="video-links">
                    <a href="https://www.youtube.com/watch?v=cKgi-XnVFVI" target="_blank" rel="noopener noreferrer" class="video-link">
                        <i class="fab fa-youtube"></i>
                        Sarcoma Information Brief 1
                    </a>
                    <a href="https://www.youtube.com/watch?v=188TWJsAFlk" target="_blank" rel="noopener noreferrer" class="video-link">
                        <i class="fab fa-youtube"></i>
                        Sarcoma Information Brief 2
                    </a>
                </div>
            </div>
        </div>
    </div>

    <!-- Imaging Tests Section -->
    <div id="imaging-tests" class="content-section imaging-section">
        <h2 class="section-title">
            <i class="fas fa-x-ray"></i>
            Imaging Tests for Leiomyosarcoma
        </h2>

        <div class="imaging-grid">
            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-x-ray"></i>
                </div>
                <h3>X-ray</h3>
                <p>Basic imaging technique for initial assessment and detection of abnormalities.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-cube"></i>
                </div>
                <h3>Computed Tomography (CT) Scan</h3>
                <p>Employed to investigate the suspected area for the presence of tumors and to ascertain whether the cancer has extended beyond its initial origin. A non-invasive, painless technique utilizing X-ray imaging to peer inside the body. Multiple images taken from various angles generate cross-sectional images of soft tissue, organs, blood vessels, and bones.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-magnet"></i>
                </div>
                <h3>Magnetic Resonance Imaging (MRI) Scan</h3>
                <p>Utilized to capture intricate, detailed images of the body's internal structures.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-atom"></i>
                </div>
                <h3>PET-CT Scan</h3>
                <p>This diagnostic modality combines a PET scan with a CT scan to discern potential cancer cell presence. During the examination, a mildly radioactive substance, in conjunction with a glucose solution, is administered. Cancer cells exhibit a swifter glucose absorption rate compared to healthy cells.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-wave-square"></i>
                </div>
                <h3>Ultrasound Imaging</h3>
                <p>This method employs sound waves to produce visual representations of organs, veins, and arteries.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-syringe"></i>
                </div>
                <h3>Needle Biopsy or Incisional Biopsy</h3>
                <p>Involves the collection of tissue samples either via a needle or through a surgical incision in the skin, which are subsequently examined for the presence of cancer cells.</p>
            </div>

            <div class="imaging-card">
                <div class="imaging-icon">
                    <i class="fas fa-heartbeat"></i>
                </div>
                <h3>Angiogram</h3>
                <p>Utilizes X-rays to examine blood vessels and assess blood flow, detecting potential blockages or leaks. A contrast agent is introduced through a catheter to evaluate the condition of the blood vessels.</p>
            </div>
        </div>
    </div>

    <!-- Treatment Options Section -->
    <div id="treatment-options" class="content-section treatment-section">
        <h2 class="section-title">
            <i class="fas fa-medkit"></i>
            Treatments for Leiomyosarcoma
        </h2>

        <div class="treatment-grid">
            <div class="treatment-card">
                <div class="treatment-icon">
                    <i class="fas fa-cut"></i>
                </div>
                <h3>Surgery</h3>
                <p>This involves tumor resection, a surgical procedure to remove the tumor along with a wide margin of healthy tissue around it. This margin is extended beyond the tumor to minimize the chances of recurrence. Surgery, with an emphasis on achieving a broad margin, has historically proven to be the most effective and preferred method of treating leiomyosarcoma.</p>
            </div>

            <div class="treatment-card">
                <div class="treatment-icon">
                    <i class="fas fa-radiation"></i>
                </div>
                <h3>Radiation Therapy</h3>
                <p>Radiation therapy is employed in some cases of leiomyosarcoma to target the tumor and destroy cancer cells while striving to preserve the function of nearby organs.</p>
            </div>

            <div class="treatment-card">
                <div class="treatment-icon">
                    <i class="fas fa-pills"></i>
                </div>
                <h3>Chemotherapy</h3>
                <p>Chemotherapy drugs, such as gemcitabine-docetaxel, are commonly used to combat and eradicate leiomyosarcoma cells. Other drugs, like trabectedin, may also be considered. Multiple drug options and combinations exist, and discussing these choices with a sarcoma specialist is advisable.</p>
            </div>

            <div class="treatment-card">
                <div class="treatment-icon">
                    <i class="fas fa-bullseye"></i>
                </div>
                <h3>Targeted Drug Therapy</h3>
                <p>Targeted drug therapy is designed to address specific molecular characteristics of the cancer. Pazopanib, an oral therapy approved for leiomyosarcoma, is frequently utilized in conjunction with chemotherapy and/or radiation therapy as part of a comprehensive leiomyosarcoma treatment strategy.</p>
            </div>

            <div class="treatment-card">
                <div class="treatment-icon">
                    <i class="fas fa-shield-virus"></i>
                </div>
                <h3>Immunotherapy</h3>
                <p>Immunotherapy is an innovative treatment approach that harnesses certain aspects of the body's immune system to combat cancer. While it is on the horizon for leiomyosarcoma, further research and development are required to establish its efficacy in treating this particular type of cancer.</p>
            </div>
        </div>
    </div>

    <!-- Medical Terminology Section -->
    <div id="medical-terminology" class="content-section terminology-section">
        <div class="terminology-card">
            <div class="terminology-header">
                <i class="fas fa-book-medical"></i>
                <h2>Medical Terminology Resource</h2>
            </div>
            <p class="terminology-description">A Cancer Glossary for Your Reference</p>
            <p>The National Cancer Institute (NCI) provides a comprehensive guide encompassing over 8,000 cancer-related terms. The NCI Dictionary serves as a user-friendly resource, aiding patients and their families in enhancing their understanding of complex medical articles.</p>
            <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" target="_blank" rel="noopener noreferrer" class="terminology-link">
                <i class="fas fa-external-link-alt"></i>
                NCI Dictionary of Cancer Terms
            </a>
        </div>
    </div>

    <!-- Circulating Tumor DNA Section -->
    <div id="ctdna-testing" class="content-section ctdna-section">
        <h2 class="section-title">
            <i class="fas fa-dna"></i>
            Clinical Circulating Tumor DNA Testing for Precision Oncology
        </h2>
        
        <div class="research-reference">
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101787/" target="_blank" rel="noopener noreferrer" class="research-link">
                <i class="fas fa-file-medical"></i>
                View Research Article
            </a>
        </div>

        <div class="research-summary">
            <h3>Research Summary</h3>
            <p>ctDNA testing requires a minimum safety resolution through clinical validation to ensure its clinical utility. The testing requires cooperation between multi-disciplinary experts to provide meaningful and reliable results. Establishing a proper clinical validation guideline for ctDNA will enable access to better cancer treatment and reliable testing in the future.</p>
        </div>

        <div class="key-findings">
            <h3>Key Findings</h3>
            <ul>
                <li>Research results suggest that ctDNA, assayed by a widely available sequencing approach, may be useful as a biomarker for a subset of patients with uterine and extrauterine LMS.</li>
                <li>Higher levels of ctDNA correlate with tumor size and disease progression.</li>
                <li>Liquid biopsies may assist in guiding treatment decisions, monitoring response to systemic therapy, surveying for disease recurrence, and differentiating benign and malignant smooth muscle tumors.</li>
                <li>LMS is frequently a clinically aggressive disease, and patients are at high risk for local and metastatic relapse after initial complete resection.</li>
            </ul>
        </div>

        <div class="clinical-uses">
            <h3>Potential Clinical Uses of ctDNA in LMS</h3>
            <div class="use-cards">
                <div class="use-card">
                    <h4>Differentiation</h4>
                    <p>ctDNA may be able to differentiate benign smooth muscle neoplasms, such as leiomyoma, from LMS.</p>
                </div>
                <div class="use-card">
                    <h4>Adjuvant Therapy Guidance</h4>
                    <p>Should ctDNA levels bear prognostic significance for tumors that are at highest risk of recurrence or identify the presence of residual disease, their measurement may help guide clinical decisions regarding adjuvant therapies.</p>
                </div>
                <div class="use-card">
                    <h4>Treatment Response</h4>
                    <p>ctDNA levels may be a useful indicator of response to systemic therapy and provide an early indication for switching or intensifying treatment regimens used in this disease.</p>
                </div>
            </div>
        </div>

        <div class="expert-quote">
            <blockquote>
                <p>"Together with technologic improvements in sensitivity and throughput, these initial reports that identify ctDNA in LMS may quickly evolve to transform clinical practice."</p>
                <cite>â€“ Dr. Matt Hemming, UMASS General Hospital, Worcester, Mass. (2019)</cite>
            </blockquote>
        </div>

        <div class="panel-video">
            <h3>Expert Panel Discussion</h3>
            <p>Assessing Circulating Tumor DNA: Current Status and Future Prospects in Sarcoma Research</p>
            <p>Panel includes Dr. Nam Quoc Bui, Dr. Brian Compton, Dr. Elizabeth Davis, Dr. Erlinda Maria Gordon, Dr. Matthew Hemming, Dr. Elise Nasif, Dr. Joanna Pryzbyl, Dr. David Schulman and Dr. Jonathan Trent. (2023)</p>
            <a href="https://www.youtube.com/watch?v=fhsyH8bJn_I" target="_blank" rel="noopener noreferrer" class="video-link">
                <i class="fab fa-youtube"></i>
                Watch Panel Presentation
            </a>
        </div>
    </div>
</div>
